Recombinant Yersinia pseudotuberculosis serotype O:3 Serine hydroxymethyltransferase (glyA)

What is Yersinia pseudotuberculosis and how does serotype O:3 differ from other serotypes?

Yersinia pseudotuberculosis is a Gram-negative bacterium belonging to the Enterobacteriaceae family, which also includes Y. pestis and Y. enterocolitica. Y. pseudotuberculosis has 21 recognized serotypes in the O-antigen-based serotyping scheme, each distinguished by differences in the O-antigen polysaccharide structures of their lipopolysaccharides . The O-antigen gene clusters in Y. pseudotuberculosis are typically located between the hemH and gsk genes .

While the search results don't specifically detail serotype O:3, we know that Y. pseudotuberculosis serotypes are classified based on their O-antigen structures. Most Y. pseudotuberculosis O-antigens are produced via the Wzx/Wzy-dependent pathway, with genes synthesizing these structures clustered between conserved hemH and gsk genes . The O-antigen is a major immunogenic feature, and serotype differences can affect bacterial pathogenicity, host immune responses, and epidemiological patterns .

What is serine hydroxymethyltransferase (SHMT) and what is its role in Y. pseudotuberculosis?

Serine hydroxymethyltransferase (SHMT), encoded by the glyA gene, is an enzyme that catalyzes the reversible conversion of serine to glycine with the transfer of a one-carbon unit to tetrahydrofolate. The enzyme plays a crucial role in amino acid metabolism and one-carbon transfer reactions essential for cellular processes including nucleotide biosynthesis.

In bacterial systems, SHMT has been shown to have substrate flexibility. For example, in Corynebacterium glutamicum, SHMT can also catalyze the aldole cleavage of L-threonine to glycine, though at a lower rate (approximately 4% of the activity with L-serine) . This suggests that SHMT may have secondary metabolic roles beyond its primary function. In Y. pseudotuberculosis, SHMT likely serves similar metabolic functions, contributing to amino acid metabolism and one-carbon transfer reactions necessary for cellular growth and survival.

Why is glyA considered an essential gene and how does this impact recombinant expression studies?

The glyA gene is considered essential in many bacteria because it encodes SHMT, which is critical for glycine biosynthesis and one-carbon metabolism. These pathways are fundamental for nucleotide synthesis, amino acid metabolism, and other vital cellular processes. In recombinant expression studies, the essential nature of glyA creates both challenges and opportunities.

When working with glyA as an essential gene, researchers must employ specialized strategies. For instance, in Corynebacterium glutamicum, researchers placed the essential glyA gene under control of an inducible Ptac promoter, making its expression dependent on isopropylthiogalactopyranoside (IPTG) . This approach allowed for controlled modulation of SHMT activity in vivo.

For recombinant expression of Y. pseudotuberculosis glyA, researchers must consider:

• Using expression systems that don't interfere with the host's native glyA function

• Potential toxicity if overexpressed

• The need for complementation strategies if attempting to modify or delete the native gene

• Potential metabolic burden on host cells when expressing a foreign essential gene

What are the optimal methods for cloning and expressing recombinant Y. pseudotuberculosis serotype O:3 glyA?

Based on previous research with SHMT from other organisms, the following methodological approach is recommended:

• Gene amplification and vector selection:

  • Amplify the glyA gene from Y. pseudotuberculosis serotype O:3 genomic DNA using high-fidelity PCR

  • Select an appropriate expression vector with a tag system (His-tag is commonly used for purification purposes)

  • Consider using a vector with an inducible promoter to control expression levels

• Expression system selection:

  • E. coli BL21(DE3) or derivatives are common choices for recombinant protein expression

  • Consider expression temperatures between 18-25°C to enhance protein solubility

  • Use rich media (like LB or TB) supplemented with appropriate antibiotics

• Protein purification:

  • Affinity chromatography using the chosen tag (e.g., Ni-NTA for His-tagged proteins)

  • Follow with size-exclusion chromatography for higher purity

  • Consider adding folate derivatives in purification buffers to stabilize the enzyme

• Activity verification:

  • Establish a spectrophotometric assay to measure SHMT activity

  • Compare activity with both serine and threonine as substrates

  • Confirm correct folding using circular dichroism or fluorescence spectroscopy

This approach is similar to that used for C. glutamicum SHMT, where researchers successfully cloned glyA with an affinity tag, expressed and purified the protein, and determined its substrate specificity .

What assays can be used to measure SHMT activity in recombinant Y. pseudotuberculosis serotype O:3 glyA?

Several assay methods can be employed to measure SHMT activity:

• Spectrophotometric coupled enzyme assays:

  • Couple SHMT reaction to another enzyme that produces a spectrophotometrically detectable product

  • For example, measuring NADH oxidation when coupling with methylenetetrahydrofolate dehydrogenase

• Radiochemical assays:

  • Use 14C-labeled serine and measure the formation of [14C]glycine and [14C]formaldehyde

  • This method provides high sensitivity but requires radioisotope handling facilities

• HPLC-based assays:

  • Separate and quantify reaction products (glycine) from substrates (serine)

  • Can be coupled with mass spectrometry for additional specificity

• Aldole cleavage activity assay:

  • Specifically for measuring threonine cleavage activity

  • Similar to the method used with C. glutamicum SHMT, which showed activity of 1.3 μmol min-1 (mg of protein)-1 with L-threonine, representing 4% of the activity with L-serine as substrate

• Colorimetric assays:

  • Measure formaldehyde production using reagents like Nash's reagent

  • Provides a simpler alternative to radiochemical methods

How can protein stability and enzymatic activity of recombinant SHMT be optimized?

Optimizing stability and activity of recombinant Y. pseudotuberculosis SHMT requires attention to several factors:

• Buffer optimization:

  • Test buffers in pH range 6.5-8.0 (typical optimum for most SHMTs)

  • Include tetrahydrofolate cofactor or analogues to stabilize the enzyme

  • Add reducing agents (1-5 mM DTT or β-mercaptoethanol) to prevent oxidation

  • Consider adding glycerol (10-20%) to enhance stability during storage

• Cofactor and substrate considerations:

  • Ensure adequate concentrations of pyridoxal 5'-phosphate (PLP), the essential cofactor

  • Pre-incubate the enzyme with PLP before activity measurements

  • Determine optimal substrate concentrations through Michaelis-Menten kinetics

• Storage conditions:

  • Store purified enzyme at -80°C in small aliquots to avoid freeze-thaw cycles

  • Test stability with different cryoprotectants (glycerol, sucrose, trehalose)

  • For short-term storage, 4°C may be suitable with appropriate stabilizing additives

• Expression modifications:

  • Co-express molecular chaperones to improve folding

  • Consider fusion partners that enhance solubility (MBP, SUMO, thioredoxin)

  • Optimize induction conditions (temperature, inducer concentration, duration)

• Site-directed mutagenesis:

  • Identify and modify residues prone to oxidation or proteolysis

  • Introduce stabilizing interactions based on structural homology modeling

  • Consider consensus sequence approaches for stability enhancement

How does Y. pseudotuberculosis serotype O:3 glyA compare to glyA from other Yersinia species in terms of sequence, structure, and function?

A comparative analysis of glyA across Yersinia species provides insights into evolutionary relationships and functional conservation:

Sequence comparison:
While the search results don't provide specific sequence data for Y. pseudotuberculosis serotype O:3 glyA, we can infer some relationships based on general genomic information about Yersinia species. Y. pseudotuberculosis is closely related to Y. pestis, with Y. pestis having emerged from a Y. pseudotuberculosis O:1b progenitor within the last 20,000 years . In contrast, Y. pseudotuberculosis and Y. enterocolitica lineages separated between 0.4 and 1.9 million years ago .

Given these evolutionary relationships, we would expect the glyA sequence from Y. pseudotuberculosis serotype O:3 to be highly similar to that of Y. pestis (likely >99% identity), and somewhat less similar to Y. enterocolitica glyA. Specific sequence differences might impact substrate specificity, reaction rates, or regulation, though core catalytic functions are likely conserved.

Structural considerations:
SHMTs generally share a conserved fold with:

• PLP binding site in the active center

• N-terminal domain involved in tetrahydrofolate binding

• Dimeric or tetrameric quaternary structure

Subtle structural differences between Yersinia SHMTs might influence:

• Substrate binding pocket architecture

• Conformational dynamics during catalysis

• Allosteric regulation

• Protein-protein interaction surfaces

Functional implications:
Functional differences may include:

• Variations in catalytic efficiency (kcat/Km) with different substrates

• Different secondary activities (like the threonine aldolase activity)

• Differential regulation in response to metabolic conditions

• Species-specific protein-protein interactions

What role does glyA play in Y. pseudotuberculosis pathogenicity and virulence?

While the search results don't explicitly connect glyA to Y. pseudotuberculosis pathogenicity, we can discuss several potential relationships based on general principles of bacterial pathogenesis:

How can structural biology approaches enhance our understanding of Y. pseudotuberculosis SHMT?

Structural biology approaches offer powerful insights into enzyme function and can guide rational protein engineering. For Y. pseudotuberculosis SHMT, the following approaches are particularly valuable:

• X-ray crystallography:

  • Determine high-resolution structures of SHMT in different states:

    • Apo-enzyme structure

    • SHMT-PLP complex

    • SHMT-substrate complexes

    • SHMT-inhibitor complexes

  • Map the active site architecture and substrate binding pocket

  • Identify potential allosteric sites for regulation

• Cryo-electron microscopy (cryo-EM):

  • Visualize large conformational changes during catalysis

  • Study SHMT in complex with other proteins in its metabolic network

  • Examine quaternary structure arrangements (dimeric/tetrameric forms)

• Nuclear magnetic resonance (NMR) spectroscopy:

  • Investigate dynamics of substrate binding and product release

  • Study conformational changes in solution

  • Examine hydrogen-deuterium exchange to identify flexible regions

• Computational approaches:

  • Molecular dynamics simulations to study protein flexibility

  • Quantum mechanics/molecular mechanics simulations for reaction mechanism

  • Homology modeling if experimental structures are unavailable

  • Virtual screening for potential inhibitors

• Small-angle X-ray scattering (SAXS):

  • Study SHMT shape and conformational changes in solution

  • Complement crystallographic data with solution-state information

These structural approaches can guide:

• Rational design of inhibitors as potential antimicrobials

• Engineering SHMT for enhanced stability or altered specificity

• Understanding the molecular basis of substrate recognition

• Elucidating the catalytic mechanism in atomic detail

What are common challenges in expressing and purifying recombinant Y. pseudotuberculosis SHMT and how can they be addressed?

Researchers working with recombinant SHMT often encounter several challenges:

• Expression challenges:

  • Problem: Low soluble expression

  • Solutions:

    • Lower expression temperature (16-20°C)

    • Co-express with chaperones (GroEL/GroES, DnaK/DnaJ)

    • Use solubility-enhancing fusion tags (MBP, SUMO)

    • Optimize codon usage for expression host

  • Problem: Toxicity to host cells

  • Solutions:

    • Use tightly regulated expression systems

    • Decrease inducer concentration

    • Shorter induction times

    • Consider cell-free expression systems

• Purification difficulties:

  • Problem: Aggregation during purification

  • Solutions:

    • Add mild detergents (0.05% Tween-20)

    • Include stabilizing agents (glycerol, arginine)

    • Maintain reducing conditions throughout purification

    • Use gradient elution to minimize concentration effects

  • Problem: Co-purification of contaminants

  • Solutions:

    • Implement multi-step purification (affinity, ion exchange, size exclusion)

    • Add wash steps with increased salt or low imidazole

    • Consider on-column refolding protocols

    • Test different affinity tags if specific contaminants persist

• Activity and stability issues:

  • Problem: Loss of activity during purification/storage

  • Solutions:

    • Supplement buffers with PLP cofactor

    • Minimize exposure to light (PLP is light-sensitive)

    • Add reducing agents to prevent oxidation

    • Store with stabilizing additives (glycerol, PLP, reducing agents)

  • Problem: Inconsistent activity measurements

  • Solutions:

    • Standardize enzyme:substrate ratios

    • Control temperature precisely during assays

    • Pre-incubate with PLP before activity assays

    • Calculate specific activity based on active enzyme concentration

• Tag removal complications:

  • Problem: Inefficient tag cleavage

  • Solutions:

    • Optimize protease digestion conditions (time, temperature, buffer)

    • Ensure accessibility of cleavage site (add flexible linkers)

    • Test alternative proteases if standard options fail

    • Consider tag-free expression if cleavage proves problematic

How can researchers analyze the kinetic properties of Y. pseudotuberculosis SHMT and interpret the results?

Comprehensive kinetic analysis of SHMT provides insights into its catalytic mechanism and substrate preferences:

• Basic kinetic parameters determination:

  • Measure initial velocities at varying substrate concentrations

  • Plot data using Michaelis-Menten, Lineweaver-Burk, or Eadie-Hofstee methods

  • Determine Km, Vmax, and kcat for both serine and threonine substrates

  • Calculate catalytic efficiency (kcat/Km) to compare different substrates

  Example table format for reporting kinetic parameters:

  Substrate	Km (mM)	kcat (s-1)	kcat/Km (M-1s-1)
  L-Serine	TBD	TBD	TBD
  L-Threonine	TBD	TBD	TBD

• Advanced kinetic analysis:

  • Study pH dependence to identify catalytic residues

  • Perform temperature-dependent studies to determine activation energy

  • Analyze product inhibition patterns to elucidate reaction mechanism

  • Conduct isotope effect studies to identify rate-limiting steps

• Data interpretation guidelines:

  • Compare with known SHMT enzymes, especially from other Yersinia species

  • Consider physiological relevance of measured parameters (are Km values in physiological concentration ranges?)

  • Evaluate dual substrate kinetics (serine vs. threonine) in context of metabolic needs

  • Assess impact of cofactors and regulators on kinetic parameters

• Analytical methods for complex kinetics:

  • Global fitting approaches for multi-substrate reactions

  • Statistical methods to distinguish between kinetic models

  • Simulation and computational modeling to visualize reaction progress

  • Integrated rate equations for complex reaction schemes

• Interpretation challenges:

  • Distinguishing between different inhibition models

  • Accounting for cooperativity in oligomeric enzymes

  • Correcting for non-specific activities

  • Relating in vitro kinetics to in vivo function

How can researchers troubleshoot issues with recombinant Y. pseudotuberculosis SHMT enzyme activity?

When facing problems with SHMT activity, a systematic troubleshooting approach is recommended:

• No detectable activity:

  • Potential causes:

    • Improper protein folding

    • Missing cofactor (PLP)

    • Inactive enzyme due to oxidation

    • Suboptimal assay conditions

  • Solutions:

    • Verify protein folding using circular dichroism or fluorescence

    • Ensure PLP is present in purification buffers and assay mixture

    • Add reducing agents (DTT, β-mercaptoethanol)

    • Test broader ranges of pH and temperature

    • Verify assay components with positive control (commercial SHMT)

• Low specific activity:

  • Potential causes:

    • Partially inactive enzyme population

    • Presence of inhibitors in the preparation

    • Suboptimal substrate concentrations

    • Incorrect protein concentration determination

  • Solutions:

    • Optimize purification to improve homogeneity

    • Include additional purification steps to remove potential inhibitors

    • Perform substrate saturation curves to ensure optimal concentrations

    • Verify protein concentration using multiple methods (Bradford, BCA, A280)

    • Consider active site titration to determine fraction of active enzyme

• Unstable activity:

  • Potential causes:

    • Protease contamination

    • Cofactor loss

    • Oxidation during storage

    • Protein aggregation

  • Solutions:

    • Add protease inhibitors to storage buffer

    • Supplement storage buffer with excess PLP

    • Increase concentration of reducing agents

    • Filter enzyme before storage and avoid freeze-thaw cycles

    • Test different storage conditions (4°C, -20°C, -80°C)

• Unexpected kinetic behavior:

  • Potential causes:

    • Allosteric regulation

    • Substrate/product inhibition

    • Formation of inactive oligomers

    • Enzyme conformation changes

  • Solutions:

    • Perform detailed kinetic analysis at different substrate/enzyme ratios

    • Examine effects of potential regulators

    • Analyze oligomeric state using size exclusion chromatography

    • Test for hysteretic behavior by varying pre-incubation conditions

What are promising research directions for studying the role of glyA in Y. pseudotuberculosis metabolism and pathogenesis?

Several promising research directions could advance our understanding of glyA in Y. pseudotuberculosis:

• Systems biology approaches:

  • Integrate glyA into genome-scale metabolic models of Y. pseudotuberculosis

  • Perform metabolic flux analysis to quantify carbon flow through SHMT-dependent pathways

  • Apply multi-omics approaches to correlate glyA expression with metabolite profiles and virulence factor production

  • Develop computational models predicting metabolic adaptations during host infection

• Host-pathogen interaction studies:

  • Investigate glyA expression during different stages of infection

  • Examine the role of one-carbon metabolism in bacterial survival within host cells

  • Study the impact of host metabolites on glyA regulation and SHMT activity

  • Develop cell culture models to assess glyA contribution to intracellular survival

• Comparative studies across serotypes:

  • Compare glyA sequence, expression, and activity across different Y. pseudotuberculosis serotypes

  • Correlate SHMT properties with serotype-specific virulence characteristics

  • Investigate potential serotype-specific regulatory mechanisms for glyA

  • Study evolutionary patterns of glyA in relation to serotype diversification

• Vaccine and therapeutic development:

  • Evaluate glyA as a potential target for antimicrobial development

  • Assess SHMT inhibitors for selective toxicity against Y. pseudotuberculosis

  • Investigate the immunogenicity of recombinant SHMT as a vaccine candidate

  • Develop small-molecule probes targeting SHMT for diagnostic applications

• Genetic engineering applications:

  • Develop glyA-based genetic tools for Y. pseudotuberculosis

  • Create conditional glyA expression systems for studying essentiality

  • Engineer SHMT variants with altered substrate specificity

  • Apply directed evolution to develop SHMT variants with enhanced properties

How can advanced technologies like CRISPR-Cas9 be applied to study glyA function in Y. pseudotuberculosis?

CRISPR-Cas9 and other advanced genetic technologies offer powerful tools for investigating glyA function:

• Precise genome editing approaches:

  • Generate point mutations in glyA to create strains with altered SHMT activity

  • Introduce reporter fusions to study glyA expression in different conditions

  • Create conditional knockdown systems for this essential gene

  • Engineer regulatory element modifications to alter glyA expression patterns

• CRISPR interference (CRISPRi) applications:

  • Develop tunable repression of glyA to create partial loss-of-function phenotypes

  • Apply CRISPRi for temporal control of glyA expression during infection

  • Combine with RNA-seq to identify genes affected by glyA modulation

  • Create CRISPRi libraries targeting metabolic genes to identify synthetic interactions

• CRISPR activation (CRISPRa) strategies:

  • Upregulate glyA expression to assess effects on metabolic flux

  • Combine with metabolomics to analyze changes in one-carbon metabolism

  • Apply CRISPRa to upstream regulators to identify control mechanisms

  • Develop multiplexed activation systems for metabolic pathway engineering

• Base and prime editing applications:

  • Introduce specific amino acid substitutions without selection markers

  • Engineer catalytic variants with altered substrate specificity

  • Create regulatory mutants to understand glyA expression control

  • Develop high-throughput mutant libraries for structure-function analysis

• Screening and selection systems:

  • Develop CRISPR-based screens for genes interacting with glyA

  • Create reporter systems to monitor glyA expression in vivo

  • Establish selection methods for identifying optimal SHMT variants

  • Apply droplet-based screening for high-throughput analysis

What potential biotechnological applications exist for recombinant Y. pseudotuberculosis SHMT?

Recombinant SHMT from Y. pseudotuberculosis offers several biotechnological applications:

• Biocatalysis applications:

  • Stereoselective synthesis of β-hydroxy-α-amino acids

  • Production of isotopically labeled amino acids for metabolic studies

  • Development of enzyme cascade systems for complex transformations

  • Immobilized enzyme technology for continuous processing

• Analytical and diagnostic tools:

  • Development of biosensors for serine/glycine detection

  • Creation of diagnostic kits for monitoring one-carbon metabolism

  • Application in enzymatic assays for folate derivatives

  • Use as a research tool for studying tetrahydrofolate-dependent reactions

• Protein engineering opportunities:

  • Engineering SHMT for enhanced thermostability for industrial applications

  • Developing variants with altered substrate specificity

  • Creating fusion proteins with complementary enzymatic activities

  • Designing SHMT variants with reduced product inhibition

• Therapeutic applications:

  • Development of SHMT inhibitors as potential antimicrobials

  • Design of SHMT-based prodrug activation systems

  • Creation of enzyme replacement therapies for metabolic disorders

  • Development of protein-based drug delivery systems

• Educational and research tools:

  • Use as a model system for teaching enzyme kinetics

  • Development of activity-based probes for metabolic research

  • Application in structural biology method development

  • Creation of standardized assay systems for comparative enzymology